英文

1. Matsuda KM, Kotani H, Yamaguchi K, Okumura T, Fukuda E, Kono M, Hisamoto T, Kawanabe R, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Okamura T, Shoda H, Fujio K, Goshima N, Sato S, Yoshizaki A※: Significance of anti-transcobalamin receptor antibodies in cutaneous arteritis revealed by proteome-wide autoantibody screening. J Autoimmun. 135: 102995, 2023.

2. Fukasawa T, Yamashita T, Enomoto A, Norimatsu Y, Toyama S, Yoshizaki-Ogawa A, Tateishi S, Kanda H, Miyagawa K, Sato S, Yoshizaki A※: The optimal use of tildrakizumab in the elderly via improvement of Treg function and its preventive effect of psoriatic arthritis. Front Immunol. 14: 1286251, 2023.

3. Fukasawa T, Yamashita T, Enomoto A, Toyama S, Yoshizaki-Ogawa A, Tateishi S, Kanda H, Miyagawa K, Sato S, Yoshizaki A※. Utility of nailfold capillary assessment for predicting pustulotic arthro-osteitis in palmoplantar pustulosis based on a prospective cohort study. J Am Acad Dermatol. 89: 984-991, 2023.

4. Kuzumi A, Norimatsu Y, Matsuda KM, Ono C, Okumura T, Kogo E, Goshima N, Fukasawa T, Fushida N, Horii M, Yamashita T, Yoshizaki-Ogawa A, Yamaguchi K, Matsushita T, Sato S, Yoshizaki A※: Comprehensive autoantibody profiling in systemic autoimmunity by a highly-sensitive multiplex protein array. Front Immunol. 14:1255540, 2023.

5. Fukasawa T, Yoshizaki-Ogawa A, Yoshizaki A※, Sato S: Impact of guselkumab on three cases of SSc accompanying psoriasis. Rheumatology. 2023, in printing.

6. Fukasawa T, Yamashita T, Enomoto A, Yoshizaki-Ogawa A, Miyagawa K, Sato S, Yoshizaki A※: Optimal treatments and outcome measures of palmoplantar pustulosis: A systematic review and network meta-analysis-based comparison of treatment efficacy. J Eur Acad Dermatol Venereol. 2023, in printing.

7. Hara M, Ueha R, Sato T, Goto T, Yoshizaki A, Sumida H, Sato S, Yamasoba T: Clinical Risk Factors for Dysphagia and Esophageal Dysmotility in Systemic Sclerosis. J Clin Med. 12: 3448, 2023..

8. Norimatsu Y, Matsuda KM, Yamaguchi K, Ono C, Okumura T, Kogo E, Kotani H, Hisamoto T, Kuzumi A, Fukasawa T, Yoshizaki-Ogawa A, Goshima N, Sato S, Yoshizaki A※: The Autoantibody Array Assay: A Novel Autoantibody Detection Method. Diagnostics. 13: 2929, 2023.

9. Matsuno A, Sumida H, Nakanishi H, Ikeyama Y, Ishii T, Omori I, Saito H, Iwasawa O, Sugimori A, Yoshizaki A, Katoh H, Ishikawa S, Sato S: Keratinocyte proline-rich protein modulates immune and epidermal response in imiquimod-induced psoriatic skin inflammation. Exp Dermatol. 2023, in printing.

10. Fukasawa T, Yoshizaki A※, Ebata S, Fukayama M, Kuzumi A, Norimatsu Y, Matsuda KM, Kotani H, Sumida H, Yoshizaki-Ogawa A, Kagebayashi H, Sato S: Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial. J Am Acad Dermatol. 89: 366-9, 2023.

11. Purevsuren M, Uehara M, Ishizuka M, Suzuki Y, Shimbo M, Kakuda N, Ishii S, Sumida H, Miyazaki M, Yamashita T, Yoshizaki A, Asano Y, Sato S, Hatano M, Komuro I: Native T1 mapping in early diffuse and limited systemic sclerosis, and its association with diastolic function. J Cardiol. 82: 100-7, 2023.

12. Matsuda KM, Yoshizaki A※, Kuzumi A, Toyama S, Awaji K, Miyake T, Sato S: Rapid improvement of systemic sclerosis-associated intestinal pseudo-obstruction with intravenous immunoglobulin administration. Rheumatology (Oxford). 62: 3139-45, 2023.

13. Hisamoto T, Suga H, Yoshizaki-Ogawa A, Sato S, Yoshizaki A※: Increased Serum Levels of Tumor Necrosis Factor-like Ligand 1A in Atopic Dermatitis. Int J Mol Sci. 24: 1813, 2023.

14. Kuzumi A, Ebata S, Fukasawa T, Matsuda KM, Kotani H, Yoshizaki-Ogawa A, Sato S, Yoshizaki A※: Long-term Outcomes After Rituximab Treatment for Patients With Systemic Sclerosis: Follow-up of the DESIRES Trial With a Focus on Serum Immunoglobulin Levels. JAMA Dermatol. 159: 374-83, 2023.

15. Fukasawa T, Enomoto A, Yoshizaki-Ogawa A, Sato S, Miyagawa K, Yoshizaki A※: The Role of Mammalian STK38 in DNA Damage Response and Targeting for Radio-Sensitization. Cancers (Basel). 15: 2054, 2023.

16. Norimatsu Y, Yoshizaki A※, Yamada T, Akiyama Y, Toyama S, Sato S: Pemphigus vulgaris with advanced hypopharyngeal and gastric cancer following SARS-CoV-2 vaccination. J Dermatol. 50: e74-5, 2023.

17. Kuzumi A, Mitsuo S, Miyake T, Sato S, Yoshizaki A※: Tocilizumab-induced organizing pneumonia in a patient with systemic sclerosis-associated interstitial lung disease. Rheumatology (Oxford). 62: SI143-4, 2023.

18. Fukasawa T, Toyama S, Enomoto A, Yoshizaki-Ogawa A, Norimatsu Y, Tateishi S, Kanda H, Miyagawa K, Sato S, Yoshizaki A※: Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort study. Rheumatology (Oxford). 62: 2418-25, 2023.

19. Yoshizaki A※, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Sato S: Involvement of B cells in the development of systemic sclerosis. Front Immunol. 13: 938785, 2022.

20. Ebata S, Yoshizaki A※, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Okiyama N, Kodera M, Hasegawa M, Sato S: Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial. Lancet Rheum. E546-55, 2022.

21. Kawanabe R, Yoshizaki A※, Matsuda KM, Kotani H, Hisamoto T, Norimatsu Y, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Sato S: Serum C-X-C Chemokine Ligand 1 Levels in Patients with Systemic Sclerosis: Relationship of Clinical and Laboratory Observations to Anti-CD20 Monoclonal Antibody Administration. Life (Basel). 12: 646, 2022.

22. Matsuda KM, Yoshizaki A※, Yamaguchi K, Fukuda E, Okumura T, Ogawa K, Ono C, Norimatsu Y, Kotani H, Hisamoto T, Kawanabe R, Kuzumi A, Fukasawa T, Ebata S, Miyagawa T, Yoshizaki-Ogawa A, Goshima N, Sato S: Autoantibody Landscape Revealed by Wet Protein Array: Sum of Autoantibody Levels Reflects Disease Status. Front Immunol. 13: 893086, 2022.

23. Ebata S, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Asano Y, Yoshizaki A※, Sato S. Predictors of Rituximab Effect on Modified Rodnan Skin Score in Systemic Sclerosis: a machine learning analysis of the DESIRES trial. Rheumatology (Oxford). 61: 4364-73, 2022.

24. Enomoto A, Fukasawa T, Terunuma H, Nakagawa K, Yoshizaki A, Sato S, Miyagawa K. Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia. Int J Hyperthermia. 39: 200-208, 2022.

25. Kuzumi A, Yoshizaki A※, Chiba K, Mitsuo S, Matsuda KM, Norimatsu Y, Nagai K, Omatsu J, Miyake T, Sato S. Genital necrosis with cutaneous thrombosis after COVID-19 mRNA vaccination. J Eur Acad Dermatol Venereol. 36: e185-e186, 2022.

26. Ikawa T, Ichimura Y, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y. The Contribution of LIGHT to the Development of Systemic Sclerosis by Modulating IL-6 and T Helper Type 1 Chemokine Expression in Dermal Fibroblasts. J Invest Dermatol. 142: 1541-51, 2022.

27. Ebata S, Yoshizaki-Ogawa A, Sato S, Yoshizaki A※: New Era in the development of systemic sclerosis. J Clin Med. 11: 4631, 2022.

28. Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A※: Pharmacotherapy of itch-antihistamines and histamine receptors as G protein-coupled receptors. Int J Mol Sci. 23: 6579, 2022.

29. Fukasawa T, Yoshizaki-Ogawa A, Enomoto A, Miyagawa K, Sato S, Yoshizaki A※: Involvement of molecular mechanisms between T/B cells and IL-23: From palmoplantar pustulosis to autoimmune diseases. Int J Mol Sci. 23: 8261, 2022.

30. Ebata S, Yoshizaki A※, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Increased Red Blood Cell Distribution Width in the First Year after Diagnosis Predicts Worsening of Systemic Sclerosis-Associated Interstitial Lung Disease at 5 Years: A Pilot Study. Diagnostics (Basel). 11: 2274, 2021.

31. Fukasawa T, Yoshizaki A※, Ebata S, Yoshizaki-Ogawa A, Asano Y, Enomoto A, Miyagawa K, Kazoe Y, Mawatari K, Kitamori T, Sato S. Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model. Elife. 2021; 10: e67209, 2021.

32. Ikawa T, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y. Endothelial CCR6 expression due to FLI1 deficiency contributes to vasculopathy associated with systemic sclerosis. Arthritis Res Ther. 23: 283, 2021.

33. Ebata S, Yoshizaki A※, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Kashiwabara K, Oba K, Sato S. Percentage of residual B cells after 2 weeks of rituximab treatment predicts the improvement of systemic sclerosis-associated interstitial lung disease. J Dermatol. 49: 179-183, 2022.

34. Kuzumi A, Yoshizaki A※, Matsuda KM, Kotani H, Norimatsu Y, Fukayama M, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Morikawa K, Kazoe Y, Mawatari K, Kitamori T, Sato S: Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun. 12: 5947, 2021.

35. Miura S, Watanabe Y, Saigusa R, Yamashita T, Nakamura K, Hirabayashi M, Miyagawa T, Yoshizaki A, Trojanowska M, Sato S, Asano Y: Fli1 deficiency suppresses RALDH1 activity of dermal dendritic cells and related induction of regulatory T cells: a possible role in scleroderma. Arthritis Res Ther. 23: 137, 2021.

36. Ebata S, Yoshizaki A(equally first)※, Oba K, Kashiwabara K, Ueda K, Uemura Y, Watadani T, Fukasawa T, Miura S, Yoshizaki-Ogawa A, Asano Y, Okiyama N, Kodera M, Hasegawa M, Sato S: Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated randomiesed, placebo-controlled trial. Lancet Rheum. 3: e489-97, 2021.

37. Numajiri H, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Kazoe Y, Mawatari K, Kitamori T, Yoshizaki A※, Sato S: B cell depletion inhibits fibrosis via suppressing pro-fibrotic macrophage differentiation in a mouse model of systemic sclerosis. Arthritis Rheumatol. 73: 2086-95, 2021.

38. Norimatsu Y, Miyagawa T, Fukui Y, Omatsu J, Toyama S, Awaji K, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y: Serum levels of tissue factor pathway inhibitor: Potential association with Raynaud’s phenomenon and telangiectasia in patients with systemic sclerosis. J Dermatol. 48: 1253-6, 2021.

39. Norimatsu Y, Yoshizaki A※, Kabeya Y, Fukasawa T, Omatsu J, Fukayama M, Kuzumi A, Ebata S, Yoshizaki-Ogawa A, Asano Y, Ichimura H, Yonezawa S, Nakano H, Sato S: The expert-level distinction of systemic sclerosis from hand photographs using the deep convolutional neural network. J Invest Dermatol. 141: 2536-9, 2021.

40. Matsuda KM, Yoshizaki A※, Kotani H, Kuzumi A, Fukayama M, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Sato S: Development of a prediction model of treatment response in patients with cutaneous arteritis: Insights from a cohort of 33 patients. J Dermatol. 48: 1021-6, 2021.

41. Ikawa T, Miyagawa T, Fukui Y, Minatsuki S, Maki H, Inaba T, Hatano M, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y: Association of serum CCL20 levels with pulmonary vascular involvement and primary biliary cholangitis in patients with systemic sclerosis. Int J Rheum Dis. 24: 711-8, 2021.

42. Awaji K, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Norimatsu Y, Ikawa T, Watanabe Y, Yoshizaki A, Sato S, Asano Y: A potential contribution of decreased serum galectin-10 levels to systemic inflammation and pulmonary vascular involvement in systemic sclerosis. Exp Dermatol. 30: 959-65, 2021.

43. Fukui Y, Nakamura K, Hirabayashi M, Miyagawa T, Toyama S, Omatsu J, Awaji K, Ikawa T, Norimatsu Y, Yoshizaki A, Sato S, Asano Y: Serum vasohibin-1 levels: A potential marker of dermal and pulmonary fibrosis in systemic sclerosis. Exp Dermatol. 30: 951-8, 2021.

44. Norimatsu Y, Yoshizaki A※, Ohno Y, Mizuno Y, Watanabe H, Kotani H, Matsuda KM, Fukayama M, Kuzumi A, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Sato S: Cutaneous sarcoidosis as a predictor of cardiac sarcoidosis. Arch Clin Biomed Res. 5: 368-75, 2021.

45. Kuzumi A, Yoshizaki A※, Ebata S, Fukasawa T, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S: Serum TARC Levels in Patients with Systemic Sclerosis: Clinical Association with Interstitial Lung Disease. J Clin Med. 10: 660, 2021.

46. Kotani H, Yoshizaki A※, Matsuda KM, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S: Serum Calponin 3 Levels in Patients with Systemic Sclerosis: Possible Association with Skin Sclerosis and Arthralgia. J Clin Med. 10: 280, 2021.

47. Ikawa T, Miyagawa T, Fukui Y, Toyama S, Omatsu J, Awaji K, Norimatsu Y, Watanabe Y, Yoshizaki A, Sato S, Asano Y: Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis. Int J Rheum Dis. 24: 260-7, 2021.

48. Omatsu J, Saigusa R, Miyagawa T, Fukui Y, Toyama S, Awaji K, Ikawa T, Norimatsu Y, Yoshizaki A, Sato S, Asano Y: Serum S100A12 levels: Possible association with skin sclerosis and interstitial lung disease in systemic sclerosis. Exp Dermatol. 30: 409-15, 2021.

49. Matsuda KM, Yoshizaki A※, Kotani H, Norimatsu Y, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S: Serum heat shock protein 27 levels in patients with systemid sclerosis: a possible biomarker of skin sclerosis. J Eur Acad Dermatol Venereol. 35: e157-9, 2021.

50. Chen A, Yoshizaki A, Miyagaki T, Streilein RD, Tedder TF, Hall RP: Regulatory B10 cells increase after rituximab therapy but not after conventional immunosuppression in patients with pemphigus. J Invest Dermatol. 141: 443-6, 2021.

51. Matsuda KM, Yoshizaki A※, Kotani H, Kuzumi A, Fukayama M, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S: Clinical significance of anti-U1 ribonucleoprotein antibody in anti-topoisomerase I antibody-positive systemic sclerosis patients: a retrospective observational study. Arch Clin Biomed Res. 5: 76-84, 2021.

52. Norimatsu Y, Yoshizaki A※, Fukasawa T, Ebata S, Oba K, Sato S: COVID-19 pandemic highlighted the importance of telemedicine in the collagen disease of systemic sclerosis. Clin Exp Rheumatol. 39: 160, 2021.

53. Saigusa R, Toyama T, Ichimura Y, Taniguchi T, Yoshizaki A, Sato S, Asano Y: A Case of Systemic Sclerosis Complicated With Portal Hypertension. J Clin Rheumatol. 27: S668-9, 2021.

54. Fukayama M, Yoshizaki A※, Fukasawa T, Ebata S, Kuzumi A, Yoshizaki-Ogawa A, Asano Y, Oba K, Sato S: IL-17F and IL-17E are related to fibrosis and vasculopathy in systemic sclerosis. J Dermatol. 47: 1287-92, 2020.

55. Ebata S, Yoshizaki A※, Fukasawa T, Asano Y, Oba K, Sato S: Rapid decrease of serum surfactant protein-D levels predicts the reactivity of rituximab therapy in systemic sclerosis-associated interstitial lung disease. J Dermatol. 47: 796-800, 2020.

56. Nakamura K, Taniguchi T, Hirabayashi M, Yamashita T, Saigusa R, Miura S, Takahashi T, Toyama T, Ichimura Y, Yoshizaki A, Trojanowska M, Fujiu K, Nagai R, Sato S, Asano Y: Altered properties of endothelial cells and mesenchymal stem cells underlying the development of scleroderma-like vasculopathy in Klf5+/-;Fli1+/- mice. Arthritis Rheumatol. 72: 2136-46, 2020.

57. Nakamura K, Ichimura Y, Tamaki Z, Yoshizaki A, Sato S, Asano Y: Acute exacerbation of interstitial lung disease with onset of myositis in systemic sclerosis patients: a report of two cases. Scand J Rheumatol. 49: 247-8, 2020.

58. Fukui Y, Miyagawa T, Toyama S, Omatsu J, Hirabayashi M, Nakamura K, Yoshizaki A, Sato S, Asano Y: Serum delta-like 4 levels: A possible association with interstitial lung disease in systemic sclerosis. J Dermatol. 47(4): e136-7, 2020.

59. Toyama S, Yamashita T, Saigusa R, Miura S, Nakamura K, Hirabayashi M, Miyagawa T, Fukui Y, Omatsu J, Yoshizaki A, Sato S, Asano Y: Decreased serum cathepsin S levels in patients with systemic sclerosis-associated interstitial lung disease. J Dermatol. 47: 1027-32, 2020.

60. Matsuda KM, Yoshizaki A※, Kuzumi A, Fukasawa T, Ebata S, Yoshizaki-Ogawa A, Sato S: Combined immunosuppressive therapy provides favorable prognosis and increased risk of cytomegalovirus reactivation in anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis. J Dermatol. 47: 483-9, 2020.

61. Miyagawa T, Taniguchi T, Saigusa R, Fukayama M, Takahashi T, Yamashita T, Hirabayashi M, Miura S, Nakamura K, Yoshizaki A, Sato S, Asano Y: Fli1 deficiency induces endothelial adipsin expression, contributing to the onset of pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford). 59: 2005-15, 2020.

62. Kazoe Y, Mawatari K, Li L, Emon H, Miyawaki N, Chinen H, Morikawa K, Yoshizaki A, Dittrich PS, Kitamori T: Lipid Bilayer-Modified Nanofluidic Channels of Sizes with Hundreds of Nanometers for Characterization of Confined Water and Molecular/Ion Transport. J Phys Chem Lett. 11: 5756-62, 2020.

63. Ikeda T, Kawakami T, Arimura Y, Ishiguro N, Ishizu A, Ito F, Ito-Ihara T, Okiyama N, Ono S, Suzuki K, Sugawara K, Seishima M, Kodera M, Tanaka M, Hasegawa M, Furukawa F, Yamaguchi Y, Yoshizaki A: Revised Committee for guidelines for the management of vasculitis, vascular disorders of the Japanese Dermatological Association. Survey of Japanese dermatological vasculitis specialists on cases of cutaneous arteritis (cutaneous polyarteritis nodosa). J Dermatol. 47: 534-7, 2020.

64. Maki H, Kubota K, Hatano M, Minatsuki S, Amiya E, Yoshizaki A, Asano Y, Morita H, Sato S, Komuro I: Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies. Int Heart J. 61: 413-8, 2020.

65. Miura S, Asano Y, Saigusa R, Yamashita T, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Yoshizaki A, Sato S, Kadono T: Regulation of skin fibrosis by RALDH1-producing dermal dendritic cells via retinoic acid-mediated regulatory T cell induction: A role in scleroderma. J Dermatol Sci. 97: 125-34, 2020.

66. Nakao T, Kazoe Y, Mori E, Morikawa K, Fukasawa T, Yoshizaki A, Kitamori T: Cytokine analysis on a countable number of molecules from living single cells on nanofluidic devices. Analyst. 144: 7200-8, 2019.

67. Enomoto A, Fukasawa T, Tsumoto H, Karube M, Nakagawa K, Yoshizaki A, Sato S, Miura Y, Miyagawa K: Prevention of calpain-dependent degradation of STK38 by MEKK2-mediated phosphorylation. Sci Rep. 9: 16010, 2019.

68. Ebata S, Yoshizaki A※, Fukasawa T, Miura S, Takahashi T, Sumida H, Asano Y, Sato S: Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease. J Dermatol. 46: 1006-13, 2019.

69. Kuzumi A, Yoshizaki A※, Fukasawa T, Ebata S, Miura S, Yoshizaki A, Sumida H, Asano Y, Sato S: Serum levels of human β-defensin 2: possible association with fibrosis and vasculopathy in patients with systemic sclerosis. J Eur Acad Dermatol Venereol. 33: e272-4, 2019.

70. Matsuda KM, Yoshizaki A※, Kuzumi A, Fukasawa T, Ebata S, Miura S, Toyama T, Yoshizaki A, Sumida H, Asano Y, Oba K, Sato S: Skin thickness score as a surrogate marker of organ involvements in systemic sclerosis: a retrospective observational study. Arthritis Res Ther. 21: 129, 2019.

71. Fukui Y, Miyagawa T, Hirabayashi M, Yamashita T, Saigusa R, Miura S, Nakamura K, Yoshizaki A, Sato S, Asano Y: Possible association of decreased serum CXCL14 levels with digital ulcers in patients with systemic sclerosis. J Dermatol. 46: 584-9, 2019.

72. Kamata M, Asano Y, Shida R, Maeda N, Yoshizaki A, Miyagaki T, Kawashima T, Tada Y, Sato S: Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid. J Dermatol. 46: e216-7, 2019.

73. Saigusa R, Yamashita T, Miura S, Hirabayashi M, Nakamura K, Miyagawa T, Fukui Y, Yoshizaki A, Sato S, Asano Y: A potential contribution of decreased galectin-7 expression in stratified epithelia to the development of cutaneous and oesophageal manifestations in systemic sclerosis. Exp Dermatol. 28: 536-42, 2019.

74. Miyagawa T, Asano Y, Saigusa R, Hirabayashi M, Yamashita T, Taniguchi T, Takahashi T, Nakamura K, Miura S, Yoshizaki A, Miyagaki T, Sato S: A potential contribution of trappin-2 to the development of vasculopathy in systemic sclerosis. J Eur Acad Dermatol Venereol. 33: 753-60, 2019.

75. Yamashita T, Asano Y, Saigusa R, Taniguchi T, Hirabayashi M, Miyagawa T, Nakamura K, Miura S, Yoshizaki A, Trojanowska M, Sato S: Cyclophosphamide Pulse Therapy Normalizes Vascular Abnormalities in a Mouse Model of Systemic Sclerosis Vasculopathy. J Invest Dermatol. 139: 1150-60, 2019.

76. Yamashita T, Asano Y, Saigusa R, Taniguchi T, Nakamura K, Miura S, Toyama T, Takahashi T, Ichimura Y, Hirabayashi M, Yoshizaki A, Miyagaki T, Sugaya M, Sato S: Increased expression of aquaporin-1 in dermal fibroblasts and dermal microvascular endothelial cells possibly contributes to skin fibrosis and edema in patients with systemic sclerosis. J Dermatol Sci. 93: 24-32, 2019.

77. Nakao M, Nakamura K, Fukasawa T, Shida R, Ito A, Ichimura Y, Takahashi T, Mitsui A, Yoshizaki A, Shibata S, Kamata M, Araki M, Watanabe R, Sato S, Asano Y: Assessment of endothelial function during the loading phase of infliximab in psoriasis: a potential predictor of its drug survival. Int J Dermatol. 58: 54-9, 2019.

78. Senda N, Miyagaki T, Oka T, Nonogaki A, Yoshizaki A, Shibata S, Sato S: Case of purpuric drug eruption probably induced by panitumumab. J Dermatol. 46: e221-2, 2019.

79. Senda N, Miyagaki T, Kamijo H, Nakajima R, Oka T, Takahashi N, Suga H, Yoshizaki A, Asano Y, Sugaya M, Sato S: Increased HMGB1 levels in lesional skin and sera in patients with cutaneous T-cell lymphoma. Eur J Dermatol. 28: 621-7, 2018.

80. Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Toyama T, Takahashi T, Ichimura Y, Noda S, Akamata K, Saigusa R, Miyazaki M, Kuwano Y, Yanaba K, Yoshizaki A, Sato S: Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study. J Dermatol. 45: 1425-33, 2018.

81. Miyagawa T, Ichimura Y, Nakamura K, Hirabayashi M, Yamashita T, Saigusa R, Miura S, Takahashi T, Toyama T, Taniguchi T, Akamata K, Yoshizaki A, Sato S, Asano Y: Progranulin overproduction due to constitutively activated c-Abl/PKC-δ/Fli1 pathway contributes to the resistance of dermal fibroblasts to the anti-fibrotic effect of tumor necrosis factor-α in localized scleroderma. J Dermatol Sci. 92: 207-14, 2018.

82. Yamashita T, Lakota K, Taniguchi T, Yoshizaki A, Sato S, Hong W, Zhou X, Sodin-Semrl S, Fang F, Asano Y, Varga J: An orally-active adiponectin receptor agonist mitigates cutaneous fibrosis, inflammation and microvascular pathology in a murine model of systemic sclerosis. Sci Rep. 8: 11843, 2018.

83. Akatsuka T, Miyagaki T, Nakajima R, Kamijo H, Oka T, Takahashi N, Suga H, Yoshizaki A, Asano Y, Sugaya M, Sato S: Decreased IL-10-producing regulatory B cells in patients with advanced mycosis fungoides. Eur J Dermatol. 28: 314-9, 2018.

84. Numajiri H, Yoshizaki A※, Fukasawa T, Ebata S, Nakamura K, Yamashita T, Saigusa R, Miura S, Hirabayashi M, Yoshizaki A, Sumida H, Asano Y, Kazoe Y, Mawatari K, Kitamori T, Sato S: Rapid alteration of serum interleukin-6 levels may predict the reactivity of i.v. cyclophosphamide pulse therapy in systemic sclerosis-associated interstitial lung disease. J Dermatol. 45: 1221-4, 2018.

85. Kuzumi A, Yoshizaki A※, Toyama S, Fukasawa T, Ebata S, Nakamura K, Yamashita T, Saigusa R, Miura S, Hirabayashi M, Yoshizaki A, Asano Y, Sato S: Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease. J Dermatol. 45: 1216-20, 2018.

86. Taniguchi T, Miyagawa T, Toyama S, Yamashita T, Nakamura K, Saigusa R, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, Sato S, Asano Y: CXCL13 produced by macrophages due to Fli1 deficiency may contribute to the development of tissue fibrosis, vasculopathy and immune activation in systemic sclerosis. Exp Dermatol. 27: 1030-7, 2018.

87. Yoshihara Y, Ishiuji Y, Yoshizaki A, Kurita M, Hayashi M, Ishiji T, Nakagawa H, Asahina A, Yanaba K: IL-10-producing Regulatory B Cells Are Decreased in Patients with Atopic Dermatitis. J Invest Dermatol. 139: 475-8, 2018.

88. Nakao M, Asano Y, Kamata M, Yoshizaki A, Sato S: Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol. 28: 538-9, 2018.

89. Numajiri H, Yoshizaki A※, Ebata S, Fukasawa T, Yamashita T, Takahashi T, Taniguchi T, Asano Y, Sato S: Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide. J Dermatol. 45: e140-1, 2018.

90. Sakamoto M, Miyagaki T, Kamijo H, Oka T, Takahashi N, Suga H, Yoshizaki A, Asano Y, Sugaya M, Sato S: Serum vascular endothelial growth factor A levels reflect itch severity in mycosis fungoides and Sézary syndrome. J Dermatol. 45: 95-9, 2018.

91. Nakajima R, Miyagaki T, Morimura S, Fukasawa T, Oka T, Yoshizaki A, Sugaya M, Sato S: Exacerbated Immune Complex-Mediated Vascular Injury in Mice with Heterozygous Deficiency of Aryl Hydrocarbon Receptor through Upregulation of Fcγ Receptor III Expression on Macrophages. J Invest Dermatol. 138: 2195-204, 2018.

92. Saigusa R, Asano Y, Taniguchi T, Hirabayashi M, Nakamura K, Miura S, Yamashita T, Takahashi T, Ichimura Y, Toyama T, Yoshizaki A, Trojanowska M, Sato S: Fli1-haploinsufficient dermal fibroblasts promote skin-localized transdifferentiation of Th2-like regulatory T cells. Arthritis Res Ther. 20: 23, 2018.

93. Saigusa R, Asano Y, Yamashita T, Takahashi T, Nakamura K, Miura S, Ichimura Y, Toyama T, Taniguchi T, Sumida H, Tamaki Z, Miyazaki M, Yoshizaki A, Sato S: Systemic sclerosis complicated with localized scleroderma-like lesions induced by Köbner phenomenon. J Dermatol Sci. 89: 282-9, 2018.

94. Nakajima R, Miyagaki T, Oka T, Takahashi N, Hirakawa M, Suga H, Yoshizaki A, Fujita H, Asano Y, Sugaya M, Sato S: IL-25 is involved in CTCL progression by establishing Th2-dominant microenvironment. Br J Dermatol. 178: 1373-82, 2018.

95. Hirabayashi M, Asano Y, Yamashita T, Miura S, Nakamura K, Taniguchi T, Saigusa R, Takahashi T, Ichimura Y, Miyagawa T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S: Possible pro-inflammatory role of heparin-binding epidermal growth factor-like growth factor in the active phase of systemic sclerosis. J Dermatol. 45: 182-8, 2018.

96. Takahashi T, Asano Y, Yamashita T, Nakamura K, Saigusa R, Miura S, Ichimura Y, Toyama T, Hirabayashi M, Taniguchi T, Yoshizaki A, Sato S: A potential contribution of psoriasin to vascular and epithelial abnormalities and inflammation in systemic sclerosis. J Eur Acad Dermatol Venereol. 32: 291-7, 2018.

97. Yoshizaki A※: Pathogenic roles of B lymphocytes in systemic sclerosis. Immunol Lett. 195: 76-82, 2018.

98. Taniguchi T, Miyagawa T, Tamaki Z, Nakamura K, Yamashita T, Saigusa R, Takahashi T, Toyama T, Ichimura Y, Yoshizaki A, Tada Y, Sugaya M, Kadono T, Sato S, Asano Y: A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis. Arch Dermatol Res. 309: 833-42, 2017.

99. Fukasawa T, Yoshizaki A※, Ebata S, Nakamura K, Saigusa R, Miura S, Yamashita T, Hirabayashi M, Ichimura Y, Taniguchi T, Asano Y, Shimizu H, Kazoe Y, Mawatari K, Kitamori T, Sato S: Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis. Arthritis Rheumatol. 69: 1879-90, 2017.

100. Suzuki H, Miyagaki T, Otobe S, Nakajima R, Oka T, Takahashi N, Kabasawa M, Suga H, Yoshizaki A, Asano Y, Sato S, Sugaya M: Increased endocan expression in lesional skin and decreased endocan expression in sera in atopic dermatitis. J Dermatol. 44: 1392-5, 2017.

101. Miyagawa T, Asano Y, de Mestier Y, Saigusa R, Taniguchi T, Yamashita T, Nakamura K, Hirabayashi M, Miura S, Ichimura Y, Takahashi T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S: Serum H-ficolin levels: Clinical association with interstitial lung disease in patients with systemic sclerosis. J Dermatol. 44: 1168-71, 2017.

102. Takahashi T, Asano Y, Taniguchi T, Yoshizaki A, Sato S: Serum LL-37 levels correlate with the efficacy of i.v. cyclophosphamide pulse for skin sclerosis and interstitial lung disease in systemic sclerosis. J Dermatol. 44: 468-9, 2017.

103. Taniguchi T, Asano Y, Fukasawa T, Yoshizaki A, Sato S: Critical contribution of the interleukin-6/signal transducer and activator of transcription 3 axis to vasculopathy associated with systemic sclerosis. J Dermatol. 44: 967-71, 2017.

104. Miyagawa T, Kadono T, Kimura T, Saigusa R, Yoshizaki A, Miyagaki T, Yamada D, Masui Y, Fujita H, Sato S: Pazopanib induced a partial response in a patient with metastatic fibrosarcomatous dermatofibrosarcoma protuberans without genetic translocations resistant to mesna, doxorubicin, ifosfamide and dacarbazine chemotherapy and gemcitabine-docetaxel chemotherapy. J Dermatol. 44: e21-2, 2017.

105. Ebata S, Yoshizaki A※, Fukasawa T, Nakamura K, Yamashita T, Miura S, Saigusa R, Ichimura Y, Takahashi T, Hirabayashi M, Taniguchi T, Akamata K, Asano Y, Sato S: Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease. Scand J Rheumatol. 46: 247-52, 2017.

106. Saigusa R, Asano Y, Nakamura K, Hirabayashi M, Miura S, Yamashita T, Taniguchi T, Ichimura Y, Takahashi T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S: Systemic Sclerosis Dermal Fibroblasts Suppress Th1 Cytokine Production via Galectin-9 Overproduction due to Fli1 Deficiency. J Invest Dermatol. 137: 1850-9, 2017.

107. Taniguchi T, Asano Y, Nakamura K, Yamashita T, Saigusa R, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, Sato S: Fli1 Deficiency Induces CXCL6 Expression in Dermal Fibroblasts and Endothelial Cells, Contributing to the Development of Fibrosis and Vasculopathy in Systemic Sclerosis. J Rheumatol. 44: 1198-205, 2017.

108. Lin L, Mawatari K, Morikawa K, Pihosh Y, Yoshizaki A, Kitamori T: Micro/extended-nano sampling interface from a living single cell. Analyst. 142: 1689-96, 2017.

109. Toyama T, Asano Y, Miyagawa T, Nakamura K, Hirabayashi M, Yamashita T, Saigusa R, Miura S, Ichimura Y, Takahashi T, Taniguchi T, Yoshizaki A, Sato S: The impact of transcription factor Fli1 deficiency on the regulation of angiogenesis. Exp Dermatol. 26: 912-8, 2017.

110. Takahashi T, Asano Y, Sugawara K, Yamashita T, Nakamura K, Saigusa R, Ichimura Y, Toyama T, Taniguchi T, Akamata K, Noda S, Yoshizaki A, Tsuruta D, Trojanowska M, Sato S: Epithelial Fli1 deficiency drives systemic autoimmunity and fibrosis: Possible roles in scleroderma. J Exp Med. 214: 1129-51, 2017.

111. Miyagaki T, Sugaya M, Oka T, Takahashi N, Kawaguchi M, Suga H, Fujita H, Yoshizaki A, Asano Y, Sato S: Placental Growth Factor and Vascular Endothelial Growth Factor Together Regulate Tumour Progression via Increased Vasculature in Cutaneous T-cell Lymphoma. Acta Derm Venereol. 97: 586-92, 2017.

112. Yamashita T, Asano Y, Taniguchi T, Nakamura K, Saigusa R, Miura S, Toyama T, Takahashi T, Ichimura Y, Yoshizaki A, Trojanowska M, Sato S: Glycyrrhizin Ameliorates Fibrosis, Vasculopathy, and Inflammation in Animal Models of Systemic Sclerosis. J Invest Dermatol. 137: 631-40, 2017.

113. Saigusa R, Asano Y, Nakamura K, Yamashita T, Ichimura Y, Takahashi T, Toyama T, Taniguchi T, Yoshizaki A, Miyazaki M, Tamaki Z, Sato S: Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease. Mod Rheumatol. 27: 618-22, 2017.

114. Takahashi T, Asano Y, Nakamura K, Yamashita T, Saigusa R, Ichimura Y, Toyama T, Taniguchi T, Yoshizaki A, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S: A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis. Br J Dermatol. 175: 1195-203, 2016.

115. Yamashita T, Asano Y, Tanighchi T, Nakamura K, Saigusa R, Takahashi T, Ichimura Y, Toyama T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S: A potential contribution of altered cathepsin L expression to the development of dermal fibrosis and casculopathy in systemic sclerosis. Exp Dermatol. 25: 287-92, 2016.

116. Nakamura K, Asano Y, Taniguchi T, Minatsuki S, Inaba T, Maki H, Hatano M, Yamashita T, Saigusa R, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S: Serum levels of IL-18 binding protein isoform; a clinical association with inflammation and pulmonary hypertension in systemic sclerosis. J Dermatol. 43: 912-8, 2016.

117. Yoshizaki A※, Taniguchi T, Saigusa R, Fukasawa T, Ebata S, Numajiri H, Nakamura K, Yamashita T, Takahashi T, Toyama T, Asano Y, Tedder TF, Sato S: Nucleosome in patients with systemic sclerosis: possible association with immunological abnormalities via abnormal activation of T and B cells. Ann Rheum Dis. 75: 1858-65, 2016.

118. Saigusa R, Asano Y, Yamashita T, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Yoshizaki A, Miyagaki T, Sugaya M, Sato S: Fli1 deficiency contributes to the downregulation of endothelial protein C receptor in systemic sclerosis: a possible role in pro-thrombotic condition. Br J Dermatol. 174: 338-47, 2016.

119. Nakao M, Asano Y, Nakamura K, Shida R, Takahashi T, Yoshizaki A, Mitsui A, Shibata S, Araki M, Watanabe R, Ikawa Y, Toyoda C, Oka H, Sato S: The development of chronic inflammatory demyelinating polyneuropathy during adalimumab treatment in a patient with psoriasis vulgaris. Eur J Dermatol. 26: 404-5, 2016.

120. Saigusa R, Asano Y, Nakamura K, Yamashita T, Ichimura Y, Takahashi T, Toyama T, Taniguchi T, Yoshizaki A, Miyazaki M, Tamaki Z, Sato S: Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosis. J Dermatol. 43: 808-10, 2016.

121. Nakamura K, Yoshizaki A※, Takahashi T, Saigusa R, Taniguchi T, Asano Y, Gonoi W, Hinata M, Shinozaki-Ushiku A, Sato S: The first case report of fatal acute pulmonary dysfunction in a systemic sclerosis patient treated with rituximab therapy. Scand J Rheumatol. 45: 249-50, 2016.

122. Yoshizaki A※: B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets. J Dermatol. 43: 39-45, 2016.

123. Yoshizaki A※, Sato S: Autoimmunity in systemic sclerosis: overview. Systemic Sclerosis: Basic and Translational Research. Takehara K, et al., Eds. Springer Publishing, Inc., New York. PP21-37, 2016.

124. Miyagawa T, Kadono T, Tanighchi T, Nakamura K, Saigusa R, Yoshizaki A, Miyagaki T, Yamada D, Masui Y, Sato S: Cutaneous apocrine carcinoma of the scrotum: A case with widespread subcutaneous induration. J Dermatol. 42: 815-7, 2015.

125. Nakamura K, Yoshizaki A※, Saigusa R, Taniguchi T, Asano Y, Sato S: The efficaty of dantrolene sodium for muscle cramps in patients with localized scleroderma. J Eur Acad Dermatol Venereol. 45:249-50, 2015.

126. Higo T, Miyagaki T, Nakamura F, Shinohara A, Asano H, Abe H, Senda N, Yoshizaki A, Fukayama M, Kurokawa M: Paraneoplastic pemphigus occurring after bendamustine and rituximab therapy for relapsed follicular lymphoma. Ann Hematol. 94: 683-5, 2015.

127. Saigusa R, Asano Y, Taniguchi T, Yamashita T, Ichimura Y, Takahashi T, Toyama T, Yoshizaki A, Sugawara K, Tsuruta D, Taniguchi T, Sato S※: Multifaceted contribution of the TLR4-activated IRF5 transcription factor in systemic sclerosis. Proc Natl Acad Sci USA. 112: 15136-41, 2015.

128. Yokoyama T, Yoshizaki A, Simon KL, Kirby MR, Anderson SM, Candotti F: Age-Dependent Defects of Regulatory B Cells in Wiskott-Aldrich Syndrome Gene Knockout Mice. PLoS One. 10: e0139729, 2015.

129. Yoshizaki A※, Sato S: Abnormal B lymphocyte activation and function in systemic sclerosis. Ann Dermatol. 27: 1-9, 2015.

130. DiLillo DJ, Weinberg JB, Yoshizaki A, Horikawa M, Bryant JM, Iwata Y, Matsushita T, Matta KM, Chen Y, Venturi GM, Russo G, Gockerman JP, Moore JO, Diehl LF, Volkheimer AD, Friedman DR, Lanasa MC, Hall RP, Tedder TF: Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function. Leukemia. 27: 170-82, 2013.

131. Ogawa A, Shimizu K, Yoshizaki A, Sato S, Kanda Y, Kumagami H, Takahashi H, Usami S: A case of palmoplantar lichen planus in a patient with congenital sensorineural deafness. Clin Exp Dermatol. 38: 30-2, 2013.

132. Shimizu K, Ogawa F, Hara T, Yoshizaki A, Muroi E, Yanaba K, Akiyama Y, Yamaoka T, Sato S: Exogenous application of hydrogen sulfide donor attenuates inflammatory reactions through the L-selectin-involved pathway in the cutaneous reverse passive Arthus reaction. J Leukoc Biol. 93: 573-84, 2013.

133. Yanaba K, Yoshizaki A, Muroi E, Ogawa F, Shimizu K, Sato S: Increased circulating soluble vascular adhesion protein-1 levels in systemic sclerosis: association with lower frequency and severity of interstitial lung disease. Int J Rheum Dis. 16: 442-7, 2013.

134. Kalampokis I, Yoshizaki A, Tedder TF: IL-10-producing regulatory B cells (B10 cells) in autoimmune disease. Arthritis Res Ther. 15: S1, 2013.

135. Shimizu K, Ogawa F, Yoshizaki A, Akiyama Y, Kuwatsuka Y, Okazaki S, Tomita H, Takenaka M, Sato S: Increased serum levels of soluble CD163 in patients with scleroderma. Clin Rheumatol. 31: 1059-64, 2012.

136. Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, Spolski R, Poe JC, Leonard WJ, Tedder TF: Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 491: 264-8, 2012.

137. Muroi E, Hara T, Yanaba K, Ogawa F, Yoshizaki A, Takenaka M, Shimizu K, Sato S: A portable dermatoscope for easy, rapid examination of periungual nailfold capillary changes in patients with systemic sclerosis. Rheumatol Int. 31: 1601-6, 2011.

138. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Ogawa F, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S: Elevated serum interleukin-27 levels in patients with systemic sclerosis: Association with T cell, B cell, and fibroblast activation. Ann Rheum Dis. 70: 194-200, 2011.

139. Yanaba K, Yoshizaki A, Muroi E, Ogawa F, Asano Y, Kadono T, Sato S: Serum CCL23 levels are increased in patients with systemic sclerosis. Arch Dermatol Res. 303: 29-34, 2011.

140. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S: Serum IL-33 levels are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Clin Rheumatol. 30: 825-30, 2011.

141. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Tedder TF, Sato S: IL-10-producing regulatory B10 cells inhibit intestinal injury in a mouse model. Am J Pathol. 178: 735-43, 2011.

142. Yoshizaki A, Yanaba K, Ogawa A, Iwata Y, Ogawa F, Takenaka M, Shimizu K, Asano Y, Kadono T, Sato S: The specific free radical scavenger edaravone suppresses fibrosis in the bleomycin-induced and tight skin mouse models of systemic sclerosis. Arthritis Rheum. 63: 3086-97, 2011.

143. Yoshizaki A, Yanaba K, Ogawa A, Asano Y, Kadono T, Sato S: Immunization with DNA topoisomerase I and Freund’s complete adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling. Arthritis Rheum. 63: 3575-85, 2011.

144. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S: Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. J Rheumatol. 38: 2193-7, 2011.

145. Yamaoka T, Fujimoto M, Ogawa F, Yoshizaki A, Bae SJ, Muroi E, Komura K, Iwata Y, Akiyama Y, Yanaba K, Shimizu K, Sato S: The roles of P- and E-selectins and P-selectin glycoprotein ligand-1 in primary and metastatic mouse melanomas. J Dermatol Sci. 64: 99-107, 2011.

146. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S: CCL13 is a promising diagnostic marker for systemic sclerosis. Br J Dermatol. 162: 332-6, 2010.

147. Bae SJ, Shimizu K, Yozaki M, Yamaoka T, Akiyama Y, Yoshizaki A, Muroi E, Hara T, Ogawa F, Sato S: Involvement of L-selectin in contact hypersensitivity responses augmented by auditory stress. Am J Pathol. 176: 187-97, 2010.

148. Tomita H, Ogawa F, Hara T, Yanaba K, Iwata Y, Muroi E, Yoshizaki A, Komura K, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S: Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis. J Rheumatol. 37: 787-91, 2010.

149. Ogawa A, Yoshizaki A, Yanaba K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S: The differential role of L-selectin and ICAM-1 in Th1-type and Th2-type contact hypersensitivity. J Invest Dermatol. 130: 1558-70, 2010.

150. Yanaba K, Yoshizaki A (equally first), Muroi E, Hara T, Ogawa F, Shimizu K, Sato S: The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol. 88: 117-22, 2010.

151. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa F, Takenaka M, Shimizu K, Asano Y, Hasegawa M, Fujimoto M, Sato S: Treatment with rapamycin prevents fibrosis in tight-skin and bleomycin-induced mouse models of systemic sclerosis. Arthritis Rheum. 62: 2476-87, 2010.

152. Koike Y, Muroi E, Yoshizaki A, Ogawa F, Yanaba K, Takenaka M, Shimizu K, Sato S: Autoantibody against surviving in patients with systemic sclerosis. J Rheumatol. 185: 2502-15, 2010.

153. Yoshizaki A, Yanaba K, Iwata Y, Komura K, Ogawa A, Akiyama Y, Muroi E, Hara T, Ogawa F, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S: Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. J Immunol. 185: 2502-15, 2010.

154. Yoshizaki A, Nakayama T, Naito S, Sekine I: Expression patterns of angiopoietin-1, -2, and tie-2 receptor in ulcerative colitis support involvement of the angiopoietin/tie pathway in the progression of ulcerative colitis. Dig Dis Sci. 54: 2094-9, 2009.

155. Tomita H, Iwata Y, Ogawa F, Komura K, Shimizu K, Yoshizaki A, Hara T, Muroi E, Yanaba K, Bae S, Takenaka M, Hasegawa M, Fujimoto M, Sato S: P-selectin glycoprotein ligand-1 contributes to wound healing predominantly as a p-selectin ligand and partly as an e-selectin ligand. J Invest Dermatol. 129: 2059-67, 2009.

156. Iwata Y, Yoshizaki A, Ogawa F, Komura K, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Takehara K, Sato S: Increased serum pentraxin 3 in patients with systemic sclerosis. J Rheumatol. 36: 976-83, 2009.

157. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Usui A, Hasegawa M, Fujimoto M, Takehara K, Sato S: Elevated circulating TWEAK levels in systemic sclerosis: association with lower frequency of pulmonary fibrosis. J Rheumatol. 36: 1657-62, 2009.

158. Komura K, Iwata Y, Ogawa F, Yoshizaki A, Yamaoka T, Akiyama Y, Hara T, Hasegawa M, Fujimoto M, Sato S: Low zone tolerance requires ICAM-1 expression to limit contact hypersensitivity elicitation. J Invest Dermatol. 129: 2661-7, 2009.

159. Iwata Y, Yoshizaki A, Komura K, Shimizu K, Ogawa F, Hara T, Muroi E, Bae S, Takenaka M, Yukami T, Hasegawa M, Fujimoto M, Tomita Y, Tedder TF, Sato S: CD19, a response regulator of B lymphocytes, regulates wound healing through hyaluronan-induced TLR4 signaling. Am J Pathol. 175: 649-60, 2009.

160. Yanaba K, Muroi E, Yoshizaki A, Hara T, Ogawa F, Shimizu K, Yozaki M, Hasegawa M, Fujimoto M, Takehara K, Sato S: Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis. J Rheumatol. 36: 1917-23, 2009.

161. Yoshizaki A, Sato S: Olopatadine hydrochloride inhibits scratching behavior induced by a proteinase-activated receptor 2 agonist in mice. J Dermatol Sci. 56: 136-9, 2009.

162. Yoshizaki A, Iwata Y, Komura K, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Tedder TF, Sato S: CD19 regulates skin and lung fibrosis via Toll-like receptor signaling in a model of bleomycin-induced scleroderma. Am J Pathol. 172: 1650-63, 2008.

163. Yoshizaki A, Kawakami A, Aramaki T, Ida H, Eguchi K: Preferential recovery by an intensive initial therapy from hemophagocytic syndrome complicated with adult onset Still’s disease presenting as agranulocytosis and hypercytokinemia. Clin Exp Rheumatol. 26: 383, 2008.

164. Yoshizaki A, Iwata Y, Komura K, Hara T, Ogawa F, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S: Clinical significance of serum hyaluronan levels in systemic sclerosis: association with disease severity. J Rheumatol. 35: 1825-9, 2008.

165. Shimizu K, Ogawa F, Akiyama Y, Muroi E, Yoshizaki A, Iwata Y, Komura K, Bae S, Sato S: Increased serum levels of N(epsilon)-(hexanoyl)lysine, a new marker of oxidative stress, in systemic sclerosis. J Rheumatol. 35: 2214-9, 2008.

166. Yoshizaki A, Komura K, Iwata Y, Ogawa F, Hara T, Muroi E, Takenaka M, Shimizu K, Hasegawa M, Fujimoto M, Sato S: Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol. 29: 180-9, 2009.

167. Komura K, Yoshizaki A, Kodera M, Iwata Y, Ogawa F, Shimizu K, Wayaku T, Yukami T, Murata M, Hasegawa M, Fujimoto M, Takehara K, Sato S: Increased serum soluble OX40 in patients with systemic sclerosis. J Rheumatol. 35: 2359-62, 2008.

168. Yakata Y, Nakayama T, Yoshizaki A, Kusaba T, Inoue K, Sekine I: Expression of p-STAT3 in human gastric carcinoma: significant correlation in tumour invasion and prognosis. Int J Oncol. 30: 437-42, 2007.

169. Nakayama T, Yoshizaki A, Izumida S, Suehiro T, Miura S, Uemura T, Yakata Y, Shichijo K, Yamashita S, Sekine I: Expression of interleukin-11 (IL-11) and IL-11 receptor alpha in human gastric carcinoma and IL-11 upregulates the invasive activity of human gastric carcinoma cells. Int J Oncol. 30: 825-33, 2007.

170. Kamachi M, Aramaki T, Tanimura S, Ichinose K, Fujikawa K, Iwamoto N, Yoshizaki A, Ida H, Kawakami A, Kohno M, Eguchi K: Activation of protein phosphatase causes alternative splicing of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): Potential effect on immune surveillance. Biochem Biophys Res Commun. 360: 280-5, 2007.

171. Nakayama T, Inaba M, Naito S, Mihara Y, Miura S, Taba M, Yoshizaki A, Wen CY, Sekine I: Expression of angiopoietin-1, 2 and 4 and Tie-1 and 2 in gastrointestinal stromal tumor, leiomyoma and schwannoma. World J Gastroenterol. 13: 4473-9, 2007.

172. Nakayama T, Yamazumi K, Uemura T, Yoshizaki A, Yakata Y, Matsuu-Matsuyama M, Shichijo K, Sekine I: X radiation up-regulates the occurrence and the multiplicity of invasive carcinomas in the intestinal tract of Apc(min/+) mice. Radiat Res. 168: 433-9, 2007.

173. Yamazumi K, Nakayama T, Kusaba T, Wen CY, Yoshizaki A, Yakata Y, Nagayasu T, Sekine I: Expression of interleukin-11 and interleukin-11 receptor alpha in human colorectal adenocarcinoma; immunohistochemical analyses and correlation with clinicopathological factors. World J Gastroenterol. 12: 317-21, 2006.

174. Nakayama T, Yoshizaki A, Naito S, Wen CY, Alipov G, Yakata Y, Sekine I: Expression of Ets-1 proto-oncoprotein in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol. 12: 1743-6, 2006.

175. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K, Nagayasu T, Sekine I: Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 15: 1445-51, 2006.

176. Yoshizaki A, Nakayama T, Yamazumi K, Yakata Y, Taba M, Sekine I: Expression of interleukin (IL)-11 and IL-11 receptor in human colorectal adenocarcinoma: IL-11 up-regulation of the invasive and proliferative activity of human colorectal carcinoma cells. Int J Oncol. 29: 869-76, 2006.

177. Yoshizaki A, Nakayama T, Naito S, Wen CY, Sekine I: Expressions of sonic hedgehog, patched, smoothened and Gli-1 in human intestinal stromal tumors and their correlation with prognosis. World J Gastroenterol. 12: 5687-91, 2006.

178. Nakayama T, Cho YC, Mine Y, Yoshizaki A, Naito S, Wen CY, Sekine I: Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol. 12: 6182-7, 2006.

179. Nakayama T, Hatachi G, Wen CY, Yoshizaki A, Yamazumi K, Niino D, Sekine I: Expression and significance of Tie-1 and Tie-2 receptors, and angiopoietins-1, 2 and 4 in colorectal adenocarcinoma: Immunohistochemical analysis and correlation with clinicopathological factors. World J Gastroenterol. 11: 964-9, 2005.

180. Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Nagayasu T, Sekine I: Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol. 58: 833-8, 2005.

181. Yoshizaki A, Nakayama T, Naito S, Sekine I: Expressions of Parathyroid Hormone-Related Protein (PTHrP) and PTH/PTHrP-Receptor (PTH/PTHrP-R) in Gastrointestinal Stromal Tumours(GISTs), Leiomyomas and Schwannomas. Scand J Gastroenterol. 39: 133-7, 2004.

182. Nakayama T, Yoshizaki A, Kawahara N, Ohtsuru A, Wen CY, Fukuda E, Nakashima M, Sekine I: Expression of Tie-1 and 2 receptors, and angiopoietin-1, 2 and 4 in gastric carcinoma; immunohistochemical analyses and correlation with clinicopathological factors. Histopathology. 44: 232-9, 2004.

和文

183. 吉崎　歩※: 他科のオンライン診療・遠隔医療の実際−皮膚科領域−. Entoni, 279:83-7, 2023.

184. 吉崎　歩※: しもやけ. 公明新聞. p6, 2023年1月8日第19773号.

185. 藤本麻記子、松田和樹、吉崎麻子、吉崎　歩、佐藤伸一：不明熱を呈し紫斑から診断した抗好中球細胞質抗体陰性好酸球性多発血管炎性肉芽腫症の１例. 臨床皮膚科. 77: 869-73, 2023

186. 川上民裕、有村義宏、池田高治、石黒直子、石津明洋、伊藤吹夕、猪原登志子、沖山奈緒子、小野さち子、鈴木和男、菅原弘二、清島真理子、小寺雅也、田中麻衣子、長谷川稔、古川福実、山口由衣、吉崎 歩: 皮膚血管炎・血管障害診療ガイドライン2023−IgA血管炎、クリオグロブリン血栓性血管炎、結節性多発動脈炎、リベド様血管症の治療の手引き2023−. 日本皮膚科学会誌. 133: 2079-134, 2023.

187. 吉崎　歩※: 全身性強皮症に対するリツキシマブ. リウマチ科. 68: 530-8, 2022.

188. 吉崎　歩※: 皮膚科領域におけるオンライン診療に対する皮膚科医の意識調査. 日本遠隔医療学会雑誌. 18: 34-8, 2022.

189. 吉崎　歩※: 混合性結合組織病. 皮膚疾患最新の治療2023-2024. 南江堂, 東京, 106, 2022.

190. 吉崎　歩※: 微少量によるタンパク質解析. 皮膚科. 科学評論社, 東京, 2: 537-44, 2022.

191. 吉崎　歩※、山下尚志、佐藤伸一: 「第121回日本皮膚科学会総会」印象記. 臨床皮膚科. 76: 840-3, 2022.

192. 吉崎　歩※: 全身性強皮症に対するリツキシマブの適応と治療法の極意. MB Derma. 326: 11-17, 2022.

193. 吉崎　歩※: 自己免疫疾患における新しい自己抗体測定系. 実験医学. 40: 2533-8, 2022.

194. 吉崎　歩※: 全身性強皮症に対するリツキシマブ医師主導治験. リウマチ科. 68: 220-8, 2022.

195. 吉崎　歩※: IgA血管炎. 皮膚科の臨床. 金原出版, 東京, 64: 795-8, 2022.

196. 吉崎　歩※: 線維化の治療. 皮膚科. 科学評論社, 東京, 1: 631-8, 2022.

197. 江畑　慧、吉崎　歩※、佐藤伸一: リツキシマブによる治療. 皮膚科.科学評論社, 東京, 1: 647-57, 2022.

198. 深澤毅倫、吉崎　歩※、佐藤伸一: IL-17を標的とした治療. 皮膚科.科学評論社, 東京, 1: 665-73, 2022.

199. 吉崎　歩※: 進歩する全身性強皮症の診療. 皮膚病診療. 44: 432-3, 2022.

200. 吉崎　歩※、佐藤伸一: 東京大学皮膚科によって開発された、全身性強皮症に対する新しい治療. 東大病院だより. 104: 8-9, 2022.

201. 吉崎　歩※: 全身性強皮症のリツキシマブによる治療. 臨床皮膚科. 76: 111-6, 2022.

202. 乗松雄大、吉崎　歩※、佐藤伸一: 新たな自己抗体検査法〜A-Cubeの妥当性と可能性〜. WHAT’s NEW in 皮膚科学 2022-2023. メディカルレビュー社, 大阪, 150-1, 2022.

203. 深澤毅倫、吉崎　歩、佐藤伸一: 抗ヒスタミン薬. 臨床と研究 99: 295-300, 2022.

204. 吉崎　歩、長谷川稔、佐藤伸一: 強皮症の新規治療. マルホ皮膚科セミナー. 275: 4-14, 2022.

205. 吉崎　歩※: 膠原病におけるB細胞標的療法. 皮膚科. 科学評論社, 東京, 1: 99-109, 2022.

206. 吉崎　歩※: 乾癬発症の病因・病態. 内科. 南江堂, 東京, 129: 9-12, 2022.

207. 吉崎　歩※: もっと知って、「乾癬（かんせん）」のこと. 東京リビング. p6, 2022年10月28日号.

208. 福井夕輝、浅野善英※、宮嵜美幾、山下尚志、住田隼一、吉崎　歩、山道信毅、佐藤伸一：胃前庭部毛細血管拡張症を合併した全身性強皮症の臨床的検討. 日本皮膚科学会誌. 131: 2023-32, 2021.

209. 吉崎　歩※: 結節性多発動脈炎. 今日の皮膚疾患治療指針 第5版. 医学書院, 東京, 2021.

210. 吉崎　歩※: 川崎病. 今日の皮膚疾患治療指針 第5版. 医学書院, 東京, 2021.

211. 吉崎　歩※: 巨細胞性動脈炎. 今日の皮膚疾患治療指針 第5版. 医学書院, 東京, 2021.

212. 吉崎　歩※: 血管炎症候群の全て　IgA血管炎. 臨床放射線. 金原出版, 東京, 66: 1185-91, 2021.

213. 吉崎　歩※: 免疫疾患におけるプロテオーム解析. 医学のあゆみ. 医歯薬出版, 277: 706-9, 2021.

214. 吉崎　歩※: 全身性強皮症 皮膚硬化に対する治療. 皮膚科膠原病 皮疹から全身を診る. 中山書店, 東京, 172-5, 2021.

215. 吉崎　歩※: 限局性強皮症に対する治療. 皮膚科膠原病 皮疹から全身を診る. 中山書店, 東京, 231-4, 2021.

216. 吉崎　歩※: 凍瘡. 今日の治療指針2021. 医学書院, 東京, 1290-1, 2021.

217. 吉崎　歩※: 皮膚科領域のオンライン診療. Current Therapy. 39: 44-7, 2021.

218. 吉崎　歩※: 全身性強皮症治療の最前線. マルホ皮膚科セミナー. 269: 11-7, 2021.

219. 吉崎　歩※： 顕微鏡的多発血管炎. 皮膚疾患 最新の治療 2021-2022. 南江堂, 東京, 85, 2021.

220. 化膿性汗腺炎診療の手引き策定委員会, 葉山 惟大, 井上 里佳, 大槻 マミ太郎, 大嶺 卓也, 門野 岳史, 黒川 一郎, 佐藤 伸一, 清水 宏, 高橋 健造, 鳥居 秀嗣, 乃村 俊史, 林 健太郎, 林 伸和, 藤田 英樹, 前川 武雄, 森田 明理, 吉崎 歩, 照井 正：化膿性汗腺炎診療の手引き2020. 日膚会誌. 131: 1-28, 2021.

221. 林　剛生、三浦俊介、岡　謙太、吉田香織、三枝良輔、吉崎麻子、管　析、吉崎　歩、浅野善英、佐藤伸一: 尋常性乾癬へのブロダルマブ投与を蜂窩織炎のため中断後、汎発型膿疱性乾癬を生じた1例. 皮膚科の臨床. 62: 27-31, 2020

222. 吉崎　歩※: Spot Light 乾癬センターを設立し治療と啓発に取り組む, 臨床のあゆみ. 田辺三菱製薬株式会社, 大阪, 108: 13-4, 2020.

223. 吉崎　歩※: 様々な合併症を引き起こす「乾癬」. 東大病院だより. 100: 8, 2020.

224. 吉崎　歩※: 強皮症センターと乾癬センターの狭間で思うこと. 臨床皮膚科, 74: 91, 2020.

225. 吉崎　歩※: 皮膚科領域におけるICT活用の可能性. WHAT’s NEW in 皮膚科学 2020-2021. メディカルレビュー社, 大阪, 38-9, 2020.

226. 吉崎　歩※: 薬疹. レジデント. 13: 40-9, 2020.

227. 吉崎　歩※、佐藤伸一：乾癬とIL-23/Th17 axis, IL-36　乾癬・ 病態の理解と治療最前線 皮膚科ベストセレクション. 中山書店, 東京, 102-7,2020.

228. 吉崎　歩※: リツキシマブによる全身性強皮症の治療. リウマチ科. 63: 538-47, 2020.

229. 吉崎　歩※: 皮膚疾患におけるJAK阻害薬の有用性. 炎症と免疫. 28: 414-9, 2020.

230. 吉崎　歩※: 強皮症における適応免疫と治療への展望. リウマチ科. 64: 534-43, 2020.

231. 吉崎　歩※: 自己反応性B細胞の病原性について. 生体の科学. 71: 573-8, 2020.

232. 吉崎　歩、川口鎮司、板東政司、藤本学. 座談会 SSc-ILDに対する新たな治療戦略 〜SENSCIS試験の結果から〜. MedicalTribune. 2020.5.14.特別企画号. p1-7

233. 吉崎　歩. 全身性強皮症治療の最前線. 皮膚科セミナー. ラジオNIKKEI. 2020.8.10放送.

234. 吉崎　歩: 全身に炎症を起こす「乾癬」 1人で悩まず早めの受診を. 日経Gooday. 2020.

235. 吉田純司、吉崎　歩、深澤毅倫、阿部雅人、竹谷晃一：間質性肺炎患者の胸部CT画像を対象とした機械学習による疾患レベルの評価.　AI・データサイエンス論文集. 1: 142-50, 2020.

236. 清家　剛、中﨑邦夫、藤野陽三、久田隆司、吉崎　歩: ガラス破片の落下による人的影響に関する研究. 日本建築学会技術報告集. 25: 39-44, 2019.

237. 川上民裕、有村義宏、池田高治、石黒直子、石津明洋、伊藤吹夕、猪原登志子、沖山奈緒子、小野さち子、鈴木和男、菅原弘二、清島真理子、小寺雅也、田中麻衣子、長谷川稔、古川福実、山口由衣、吉崎 歩: 皮膚動脈炎(皮膚型結節性多発動脈炎)の全国アンケート調査結果. 日本皮膚科学会誌. 129: 1901-7, 2019.

238. 吉崎　歩※: 強皮症に対する個別化医療の必要性とその可能性. Precision Medecine. 2: 30-3, 2019.

239. 吉崎　歩※: 強皮症における血小板マイクロパーティクルと好中球NETsのかかわり. リウマチ科. 61: 472-80, 2019.

240. 吉崎　歩※: 膠原病治療関連合併症②ヒドロキシクロロキン・生物学的製剤・IVIG・DDS・PAH治療約. MB Derma. 290: 25-32, 2019.

241. 吉崎　歩※: 暖かくなっても治らないしもやけ. 内科医のための皮膚疾患アトラス. 診断と治療社, 東京, 214-6, 2019.

242. 吉崎　歩※: B細胞研究から自己免疫疾患の病態に迫る. Viento. メディカル・プロフェショナル・リレーションズ株式会社, 東京, 8: 5-6, 2019.

243. 江畑慧、吉崎　歩※、佐藤伸一: CQ16 皮疹の治療にステロイド外用薬は有用か？ 全身性エリテマトーデス診療ガイドライン2019. 厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究(自己免疫班)/日本リウマチ学会, 南山堂, 東京, 92-4, 2019.

244. 深澤毅倫、吉崎　歩※、佐藤伸一: CQ17 皮疹の治療にタクロリムス外用薬は有用か？ 全身性エリテマトーデス診療ガイドライン2019. 厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究(自己免疫班)/日本リウマチ学会, 南山堂, 東京, 95-8, 2019.

245. 吉崎　歩※、佐藤伸一：リツキシマブによって救命しえた重症の全身性強皮症合併間質性肺炎. 皮膚病診療. 40: 39-42, 2018.

246. 加藤真梨子、増井友里、仙田尚之、赤塚太朗、中村洸樹、吉崎 歩、山田大資、宮垣朝光、糸魚川彩、菊池かな子、佐藤伸一: 右腋窩副乳過誤腫の1例. 皮膚科の臨床. 60: 1633-6, 2018.

247. 尾松 淳、赤股 要、永井幸司郎、遠山 聡、高橋岳浩、吉崎 歩、浅野善英、佐藤伸一: 足趾骨髄炎の治療中に生じたメトロニダゾール脳症の1例. 皮膚科の臨床. 60: 1244-8, 2018.

248. 吉崎　歩※: マイオピニオン 医師主導治験の実際 立案から開始まで. 臨床皮膚科. 医学書院, 東京, 72: 102-3, 2018.

249. 吉崎　歩※、佐藤伸一: 全身性強皮症. エキスパートから学ぶ皮膚病診療パワーアップ. 中山書店, 東京, 344-9, 2018.

250. 吉崎　歩※: 全身性強皮症の治療の実際. 強皮症を正しく理解するための本. 医薬ジャーナル社, 大阪, 59-74, 2018.

251. 吉崎　歩※、佐藤伸一: 強皮症の皮膚病変に対するリツキシマブの効果. リウマチ科. 60: 617-23, 2018.

252. 吉崎　歩※: オーバーラップ症候群. 皮膚疾患最新の治療2019-2020. 南江堂, 東京, 89, 2018.

253. 吉崎　歩※: B細胞サブセットの作用と役割. 分子リウマチ治療. 11: 29-31, 2018.

254. Mori E, Hosoya Y, Yoshizaki A, Kitamori T: Investigation of preservation stability for a small amount of patient samples using microfluidic device. Bunseki Kagaku. 66: 453-7, 2017.

255. 諫見有紀、吉崎　歩※、佐藤伸一: CPNと診断しうるPAN 皮膚病診療. 39: 385-8, 2017.

256. 吉崎　歩※: 水疱性ループス　ループスエリテマトーデスに伴う特異的皮疹. Visual Dermatology. 秀潤社, 東京, 16: 762-4, 2017.

257. 吉崎　歩※: これがlupus erythematosus (LE) Tumidusだ！　皮膚アレルギーフロンティア. メディカルレビュー社, 大阪, 15: 56, 2017.

258. 吉崎　歩※: アトラス その他の膠原病. 皮膚科研修ノート. 診断と治療社, 東京, 2016.

259. 吉崎　歩※: B細胞を中心とした全身性強皮症における免疫学的異常と治療戦略 B cell abnormalities and therapeutic strategies in systemic sclerosis Jpn J Clin Immunol. 39: 197-206, 2016.

260. 吉崎　歩※: PD-1のメラノーマ以外での役割. WHAT’s NEW in 皮膚科学 2016-2017. メディカルレビュー社, 大阪, 28-9, 2016.

261. 吉崎　歩※: 強皮症の基礎と臨床. B細胞をターゲットとした治療. 強皮症の基礎と臨床〜病態の解明から最新の診療まで〜. 佐藤伸一(編), 医薬ジャーナル社, 大阪, 232-40, 2016.

262. 吉崎　歩※: 強皮症の基礎と臨床. 強皮症と妊娠. 強皮症の基礎と臨床〜病態の解明から最新の診療まで〜. 医薬ジャーナル社, 大阪, 256-62, 2016.

263. ◎吉崎　歩※: アトピー性皮膚炎に対する生物学的製剤治療. 医学のあゆみ. 256: 107-12, 2016.

264. 吉崎　歩※、Tedder TF: 制御性B細胞の分化誘導因子と作用機序に関する検討　IL-21 induces regulatory B cell differentiation and immunosuppressive effect through cognate interaction with T cells. Jpn J Clin Immunol. 38: 57-64, 2015.

265. 吉崎　歩※, 佐藤伸一: 全身性強皮症/膠原病 全身性強皮症. ガイドライン外来診療2015. 日経メディカル開発, 東京, 523-5, 2015.

266. 吉崎　歩※: 皮膚硬化をきたす疾患 限局性強皮症. Visual Dermatology. 秀潤社, 東京, 15: 44-5, 2015.

267. 吉崎　歩※: 乾癬の病態と治療: 最新の進歩 関節症性乾癬の診断と治療. Pharma Medica. メディカルレビュー社, 大阪, 33: 23-6, 2015.

268. 吉崎　歩※、佐藤伸一: 新たな難病対策に向けて-診断基準、重症度分類 強皮症. リウマチ科. 54: 29-33, 2015.

269. 吉崎　歩※, 佐藤伸一: RAの合併症-皮膚病変. リウマチクリニックQ&A集成. メディカルレビュー社, 大阪, 2015.

270. 吉崎　歩※、佐藤伸一: 特集「ここまで変わった！子供のアレルギー診療」乳幼児への「眠気の少ない」抗ヒスタミン薬選択について. チャイルドヘルス. 診断と治療社, 東京, 18: 52-5, 2015.

271. 吉崎　歩※: 制御性B細胞. Keynote R･A. 2: 128-33, 2014.

272. 宮垣朝光、菅谷 誠、仙田尚之、岡 知徳、吉崎 歩、佐藤伸一、伊藤雄太、奥村恵子、神山泰介: ゲムシタビンが著効した胃浸潤が疑われた菌状息肉症の1例. Skin Cancer. 30: 129, 2015.

273. 吉崎　歩※、浅野善英、簗場広一、佐藤伸一: ラパマイシンによる創傷治癒遅延と細胞増殖因子の効果について Delayed wound healing by treatment of Rapamycin and the effect of growth factors. 皮膚の科学. 11: 39-44, 2012.

274. 吉崎　歩※: 疾患からみたサイトカイン. IL-22. 分子リウマチ治療. 5: 36-9, 2012.

275. 吉崎麻子、吉崎　歩、穐山雄一郎、竹中　基、佐藤伸一、西本勝太郎※: 下腿に発症したMycobacterium marinum感染症の1例 西日本皮膚科. 73: 162-5, 2011.

276. 吉崎麻子、吉崎　歩、室井栄治、小川文秀、佐藤伸一: 抗RNAポリメラーゼ抗体陽性全身性強皮症に伴った指端壊疽の1例 西日本皮膚科. 73: 221-4, 2011.

277. 吉崎麻子、吉崎　歩、鍬塚　大、竹中　基、西本勝太郎、宇谷厚志※: 小児の頸部に生じたスポロトリコーシスの1例 日本小児皮膚科学会雑誌. 30: 55-7, 2011.

278. 吉崎　歩※: エリテマトーデス類縁疾患 Lupus erythematosus tumidusとはどのような疾患か. 診る・わかる・直す 皮膚科臨床アセット7 皮膚科膠原病診療のすべて. 中山書店, 東京, 107-9, 2011.

279. 吉崎　歩※: 全身性強皮症 最新研究からのインサイト 抗線維化作用が期待される新規治療法. 診る・わかる・直す 皮膚科臨床アセット7 皮膚科膠原病診療のすべて. 中山書店, 東京, 169-71, 2011.

280. 吉崎　歩※: 全身性強皮症 抗IL-6受容体抗体. 診る・わかる・直す 皮膚科臨床アセット7 皮膚科膠原病診療のすべて. 中山書店, 東京, 338-40, 2011.

281. 吉崎　歩※: 膠原病の新規治療法 造血幹細胞移植. 診る・わかる・直す 皮膚科臨床アセット7 皮膚科膠原病診療のすべて. 中山書店, 東京, 348-50, 2011.

282. 吉崎　歩※: 膠原病の新規治療法 免疫グロブリン大量静注療法. 診る・わかる・直す 皮膚科臨床アセット7 皮膚科膠原病診療のすべて. 中山書店, 東京, 351-3, 2011.

283. 簗場広一、吉崎　歩、佐藤伸一: ブレオマイシン誘発強皮症モデル研究の進歩. リウマチ科. 46: 268-75, 2011.

284. 小川麻子、吉崎　歩、室井栄治、小川文秀、佐藤伸一: Watermelon stomachを生じた全身性強皮症の2例 日本皮膚科学会誌. 120: 1491-5, 2010.

285. 吉崎　歩、穐山雄一郎、簗場広一、小川麻子、室井栄治、小川文秀、佐藤伸一: 全身性強皮症合併間質性肺炎に対するシクロホスファミドパルス療法後の維持療法としてミゾリビンを用いた2例 日本皮膚科学会誌. 120: 1659-64, 2010.

286. 吉崎　歩※、佐藤伸一: 強皮症の病態形成における活性酸素の役割. リウマチ科. 43: 302-8, 2010.

287. 吉崎　歩、佐藤伸一: ベポタスチンベシル酸塩は一酸化炭素供与体によって誘発される掻痒行動を抑制する. 臨牀と研究. 86: 759-62, 2009.

288. 山岡俊文、室井栄治、裵 祥宰、吉崎　歩、佐藤伸一:
エバスチンはL-selectinの切断を促進する. 臨牀と研究. 86:1051-3, 2009.

289. 吉崎　歩※、佐藤伸一: 自己免疫疾患に伴う皮膚病変 強皮症における皮膚硬化の免疫学的病態. リウマチ科. 41: 143-51, 2009.

290. 岩田洋平、吉崎　歩、小村一浩、小川文秀、清水和宏、佐藤伸一: CD19欠損による創傷治癒遅延と細胞増殖因子の効果について.
皮膚の科学. 8: 52-7, 2009.

291. 吉崎　歩、岩田洋平、小村一浩、小川文秀、佐藤伸一: マウス接触性皮膚炎においてロラタジンはPSGL-1の機能を抑制する. 臨牀と研究. 85: 1755-9, 2008.

292. 池原　進、室井栄治、穐山雄一郎、吉崎　歩、佐藤伸一: 分子標的治療薬ソラフェニブによる手足症候群の5例 日本皮膚科学会誌. 119: 1091-5, 2008.

293. 小川麻子、吉崎　歩、飯塚　大、竹中　基、佐藤伸一、西本勝太郎: スポロトリコーシスの2例ー長崎地方における症例の治療効果の検討ー 皮膚科の臨床. 52:947-51, 2008.